Sökning: WFRF:(Nordenskjöld Bo 1940 ) >
Is risk of central ...
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial
-
Pestalozzi, B. C. (författare)
-
Francis, P. (författare)
-
Quinaux, E. (författare)
-
visa fler...
-
Dolci, S. (författare)
-
Azambuja, E. (författare)
-
Gelber, R. D. (författare)
-
Viale, G. (författare)
-
Balil, A. (författare)
-
Andersson, M. (författare)
-
- Nordenskjöld, Bo, 1940- (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US
-
Gnant, M. (författare)
-
Gutierrez, J. (författare)
-
Láng, I. (författare)
-
Crown, J. P. A. (författare)
-
Piccart-Gebhart, M. (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2008
- 2008
- Engelska.
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 19:11, s. 1837-1841
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Breast cancer central nervous system (CNS) metastases are an increasingly important problem because of high CNS relapse rates in patients treated with trastuzumab and/or taxanes. Patients and methods: We evaluated data from 2887 node-positive breast cancer patients randomised in the BIG 02-98 trial comparing anthracycline-based adjuvant chemotherapy (control arms) to anthracycline-docetaxel-based sequential or concurrent chemotherapy (experimental arms). After a median follow-up of 5 years, 403 patients had died and detailed information on CNS relapse was collected for these patients. Results: CNS relapse occurred in 4.0% of control patients and3.7% of docetaxel-treated patients. CNS relapse occurred in 27% of deceased patients in both treatment groups. CNS relapse was usually accompanied by neurologic symptoms (90%), and 25% of patients with CNS relapse died without evidence of extra-CNS relapse. Only 20% of patients survived 1 year from the diagnosis of CNS relapse. Prognosis of CNS relapse was worse for patients with meningeal carcinomatosis when compared with brain metastases. Unexpected findings included a higher rate of positive cerebrospinal fluid cytology (8% versus 3%) and more frequent use of magnetic resonance imaging for diagnosis (47% versus 30%) in the docetaxel-treated patients. Conclusion: There is no evidence that adjuvant docetaxel treatment is associated with an increased frequency of CNS relapse. © The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Pestalozzi, B. C ...
-
Francis, P.
-
Quinaux, E.
-
Dolci, S.
-
Azambuja, E.
-
Gelber, R. D.
-
visa fler...
-
Viale, G.
-
Balil, A.
-
Andersson, M.
-
Nordenskjöld, Bo ...
-
Gnant, M.
-
Gutierrez, J.
-
Láng, I.
-
Crown, J. P. A.
-
Piccart-Gebhart, ...
-
visa färre...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Linköpings universitet